A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus
Open Access
- 1 June 2001
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (11) , 846-854
- https://doi.org/10.1038/sj.gt.3301459
Abstract
Fully deleted adenovirus vectors (FD-AdVs) would appear to be promising tools for gene therapy. Since these vectors are deleted of all adenoviral genes, they require a helper adenovirus for their propagation. The contamination of the vector preparation by the helper limits the utility of currently existing FD-AdVs in gene therapy applications. We have developed an alternative system for the propagation of FD-AdVs, in which the adenoviral genes essential for replication and packaging of the vector are delivered into producer cells by a baculovirus–adenovirus hybrid. A hybrid baculovirus Bac-B4 was constructed to carry a Cre recombinase-excisable copy of the packaging-deficient adenovirus genome. Although the total size of the DNA insert in Bac-B4 was 38 kb, the genetic structure of this recombinant baculovirus was stable. Bac-B4 gave high yields in Sf9 insect cells, with titers of 5 × 108p.f.u./ml before concentration. Transfection of 293-Cre cells with lacZ-expressing FD-AdV plasmid DNA followed by infection by Bac-B4 at a MOI of 2000 p.f.u./ml resulted in rescue of the helper-free vector. Subsequent passaging of the obtained FD-AdV using Bac-B4 as a helper resulted in ∼ 100-fold increases of the vector titer at each passage. This resulting vector was completely free of helper virus and was able to transduce cultured 293 cells. However, scaling-up of FD-AdV production was prevented by the eventual emergence of replication-competent adenovirus (RCA). Experiments are underway to optimize this system for the large-scale production of helper virus-free FD-AdVs and to minimize the possibility of generation of replication-competent adenovirus (RCA) during vector production. This baculovirus-based system will be a very useful alternative to current methods for the production of FD-AdVs.Keywords
This publication has 52 references indexed in Scilit:
- Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vectorGene Therapy, 1997
- Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vectorEuropean Journal of Immunology, 1995
- Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 MutantsHuman Gene Therapy, 1995
- Characterization of an Adenovirus Gene Transfer Vector Containing an E4 DeletionHuman Gene Therapy, 1995
- Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector.Proceedings of the National Academy of Sciences, 1995
- MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenovirusesImmunity, 1994
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994
- Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.Proceedings of the National Academy of Sciences, 1994
- Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.Proceedings of the National Academy of Sciences, 1994
- The murine cellular immune response to adenovirus type 5Immunology & Cell Biology, 1989